HLA-A*24:02 LY6K Tetramer-RYCNLEGPPI-BV421

The α3 mutation significantly reduces the binding of MHC tetramer to human CD8. To minimizes the aberrant effect of some CD8 antibodies; clone SFCI21Thy2D3 (also known as “T8”) is recommended.

Target: Cancer

Product Type: Tetramer

Application: FCM

Conjugate: BV421

Class: Class I

Species Reactivity: Human

Allele: HLA-A*24:02

Peptide Sequence: LY6K

Research Area: Immunology, Immune Monitoring

Protocols: FCM

Specificity: LY6K

Regulatory Statement: For Research Use Only. Not for use in diagnostic procedures.